Yüklüyor......
Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
Deferasirox (DFX) is an oral iron chelator used to reduce iron overload (IO) caused by frequent blood cell transfusions in anemic myelodysplastic syndrome (MDS) patients. To study the molecular mechanisms by which DFX improves outcome in MDS, we analyzed the global gene expression in untreated MDS p...
Kaydedildi:
| Yayımlandı: | Pharmaceuticals (Basel) |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7825690/ https://ncbi.nlm.nih.gov/pubmed/33430232 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14010041 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|